ReviewGastro hep advances2025
Effect of Cystic Fibrosis Transmembrane Conductance Regulator Modulators on Liver Enzymes Among Patients With Cystic Fibrosis: A Systematic Review and Meta-Analysis.
Review in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Decoding liver injury in cystic fibrosis: How to tell drug-induced liver injury from cystic fibrosis liver disease.World journal of gastroenterology · 2026Review
- Pathophysiology of cystic fibrosis-related liver disease.Current opinion in gastroenterology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Backgrounds and Aims: This paper seeks to use existing literature to investigate the use of Cystic Fibrosis Transmembrane Conductance (CFTR) modulators and their safety and effects on the liver enzymes of cystic fibrosis (CF) patients with and without related liver disease (CFLD). This review examines the effect of CFTR modulators on liver enzymes as well as their safety profile. Methods: A comprehensive literature review across Pubmed/Medline, Embase, CINAHL, Cochrane, and Web of Science, was performed. Six articles pertaining to CFTR modulator use and liver enzyme information were included. Statistical evaluation was completed using random-effect models with a 95% confidence interval (CI), and group mean differences were analyzed with R software. Forest plots were generated for the observed effect, CI, and the weight of each study. The primary outcome was changes to serum levels of alanine transaminase (ALT), aspartate transaminase, total bilirubin, and gamma-glutamyl transferase. Secondary outcomes for this study were changes in serum biomarkers and type of CFTR modulator used. Other outcomes explored include the safety of CFTR modulator use. Results: Patients treated with lumacaftor/ivacaftor had a significant decrease in total bilirubin (-0.70 (-1.26, -0.14); Conclusion: CFTR modulators may influence levels of liver enzymes in CF patients without an increased risk of adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.